| Literature DB >> 34149352 |
Deepanjali Dwivedi1,2,3, Upinder S Bhalla1.
Abstract
SK,Entities:
Keywords: HCN and M channels; SK; advances and challenges; ion channels; neuropsychaitric disorders; therapeutic targets
Year: 2021 PMID: 34149352 PMCID: PMC8209339 DOI: 10.3389/fnmol.2021.658435
Source DB: PubMed Journal: Front Mol Neurosci ISSN: 1662-5099 Impact factor: 5.639
Summary of the regional expression of different mAHP channels in distinct brain regions and the specific subcellular and region-specific distribution of various channel isoforms.
| SK | Hippocampus (CA1, CA2, CA3 pyramidal cells, DG neurons, Internueorns) | • SK1 and SK2 are the predominant channel isoforms present in the hippocampus and cortex, while SK3 is predominant in the striatum, medial habenular nucleus, locus coeruleus, dorsal raphe, and thalamus. | |
| Cortex (piriform cortex, entorhinal cortex, para-, pre- subiculur cortex | Further, the two isoforms of SK2, SK2-S, and SK2-L also have a differential expression within a neuron. SK2-L is present in the postsynaptic density (PSD) while SK2-S localizes in extrasynaptic sites, when not in a multimeric complex with SK2-L ( | ||
| Cerebellum (Deep nuclei, purkinje cells, golgi cells, granule cells) | • Within the spinal cord, SK2 is present in all the α-motoneurons, while SK3 is preferentially present in small diameter α-motoneurons ( | ||
| Amygdala (Basolateral, Basomedial and Lateral amygdaloid nucleus) | • Within the hippocampus, SK channels are present throughout a neuron, i.e., in soma, dendrites, and spines ( | ||
| Nucleus basilis neurons, Paraventricular neurons | • SK3 channels have presynaptic localization in the hippocampus, present in mossy fibers terminals but not in pyramidal layer ( | ||
| Striatal cholinergic interneurons and Basal nuclei | • Within the brain, HCN1 is enriched in the neocortex, CA1 hippocampus, superior colliculus, fornix, superior colliculus, hypoglossal nucleus, cochlear nuclei, olfactory bulb, layer II and V in cortex and cerebellum. | ||
| Olfactory system, Neocortex, septum, Brain stem | • Unlike HCN1, HCN2 has ubiquitous expression throughout the brain. High levels are observed in the cortex, hippocampus, globus pallidus, brain stem, retina, olfactory bulb, cerebellum, and thalamus. | ||
| Striatum, Medial habenular nucleus, Locus coeruleus and dorsal raphe and Thalamus | • Both HCN3 and HCN4 are relatively lesser in the brain. • HCN3 is present at moderately higher levels in the olfactory bulb, in the piriform cortex, preoptic area, hypothalamic regions, and cochlear nuclei. | ||
| HCN | Thalamus (Principal relay nuclei, Geniculate nuclei, Subthalamic nuclei) | • HCN4 is enriched especially in olfactory bulb, thalamus, fasciculus retroflexus, substantia nigra and habenula with low levels of expression in hippocampus and dentate granule cells ( | |
| Cortex (Neocortex, Piriform Cortex, Anterior Cingulate cortex) | • Peripheral nervous system expresses all the HCN isoforms, but HCN1 levels are higher than other isoforms ( | ||
| Hippocampus (CA1, CA3, Stratum Oriens, Stratum Radiatum, Granule cells) | • In hippocampal and neocortex neurons, HCN channels had a proximal to distal dendritic gradient with limited somatic localization. They have a higher expression in the dendritic shafts than spines ( | ||
| Amygdala (Basolateral nucleus, central nucleus, lateral nucleus) | • In the medial perforant pathway, HCN1 channels are localized only on axons ( | ||
| Cerebellum (Molecular, Purkinje, Granule cell layer and deep cerebellar nuclei) | • In medial superior olive neurons, HCN channels are present in axon initial segment (AIS) and control spike threshold ( | ||
| DRG, primary nociceptive neurons | • Within thalamus, HCN2 and HCN4 channels have opposite gradient such that HCN2 channels are more abundantly present in ventrobasal (VB) neurons while HCN4 channels are predominant in reticular thalamic neurons (RTN) neurons ( | ||
| Hypothalamus (Preoptic nuclei, Ventromedial nuclei and mammillary nuclei) | • Kv7.2-Kv7.5 are the primary isoforms which constitute the M currents in the brain. | ||
| Brain Stem (Dorsal horn and Ventral horn) | • M channels are primarily present in axon initial segment, nodes of Ranvier, and on unmyelinated axons ( | ||
| Habenula (Lateral and Medial habenula) | • In CA1 hippocampal neurons, M channels are present in the perisomatic region regulating somatic excitability but not in distal dendrites ( | ||
| Kv7 | Hippocampal (CA1, CA2, CA3 pyramidal cells, DG neurons, Internueorns) | • In the hippocampus, hilar polymorphic cells, and subiculum pyramidal cells, both Kv7.2.and 7.3 were expressed. However, on mossy fiber bundles and neuropil of dentate hilus, CA3, CA1, and subiculum only Kv7.2 channels were found ( | |
| Thalamus [Medial Geniculate nucleus, Ventral posterior thalamic complex, dorsal lateral geniculate (dLG)] | • Kv7.5 channels localize in synapses of auditory nuclei ( | ||
| olfactory bulb (Granular, Mitral and Periglomerular cell layer) | • In the sciatic nerve, the nodes of Ranvier of large fibers expressed only Kv7.2. On the contrary, both Kv7.2 and Kv7.3 channel isoforms showed expression at nodes of small and intermediate-sized fibers ( | ||
| Habenula | • Mesencephalic dopaminergic neurons exclusively express Kv7.4 channel isoform ( | ||
| basal ganglia (Caudate/Putamen, accumbens nucleus, Globus Pallidus) | |||
| amygdala, | |||
| midbrain, hypothalamus, substantia nigra (Pars reticulate, Pars compacta), cerebellum (Granule, molecular, purkinje cell layer and deep nuclei) | |||
| superior cervical ganglion cells, motor neurons, dorsal horn and spinal neurons | |||
| Visceral sensory neurons, DRG, nodose ganglia, |
FIGURE 1mAHP channel structures. The three mAHP channel subunits have a similar basic structure, which consist of six transmembrane segments, but significant heterogeneity is observed at the N and C termini. (A) HCN channels open in response to hyperpolarization and conduct a net inward current through the influx of Na+ and Ca+ and efflux of K+. The CNBD at the C terminus serves as the binding site for cAMP or cGMP, which regulates HCN channel activity. (B) SK channels are calcium-dependent potassium-conducting channels regulated by bound protein kinases and phosphatases at the N and C termini. (C) Kv7/M channels are voltage-sensitive potassium channels that are regulated by PIP2 and several protein kinases that bind to the C terminus of the protein.
FIGURE 2Localization and regulatory pathways of the mAHP channels. (A) A neuron schematic illustrating the localization of the three mAHP channels. SK channels are localized on the spines and modulate synaptic response. Kv7/M channels present in the axon initial segment and node of Ranvier control cellular resting membrane potential (RMP) and input resistance (IR). HCN channels in hippocampal neurons are present as an increasing gradient from proximal to distal dendrites. (B) SK channels present on the spines are regulated by calcium influx from multiple sources; the primary sources include voltage-dependent calcium channels, ionotropic and metabotropic glutamate receptors, and CICR. (C). PIP2 levels and intracellular calcium via CaM serve as the most critical Kv7/M channel regulators. (D) Changes in intracellular cAMP levels augment HCN channel activity through cAMP binding on the CNBD on the channel. (E) Various signaling and regulatory proteins co-exist in the intracellular milieu, modulating mAHP channels and regulating cellular excitability.
Summary of different mAHP channels’ inhibitors and activators.
| • Both apamin and scyllatoxin block the pore region between S5 and S6, thereby inhibiting current flow through SK channels. Low levels of apamin can block SK2 channels (IC50 62 pM), while apamin levels as high as 100 nm cannot block SK1 channels • They bind through their basic amino acid, arginine, on the negatively charged residues in the pore region of SK channels. • d-tubocurarine can block SK2 channels at a considerably lower level (IC50 5.4 μM) than SK1 (IC50 354.3 μM) channels. SK3 has intermediate sensitivity to apamin and d-tubocurarine. • Structural heterogeneity and minor differences in the amino acids in the pore region of different SK isoforms leads to variation in sensitivity to apamin and d-tubocurarine binding. • NS8593 is a highly potent negative modulator of SK channels. It acts by increasing the response threshold of SK channels to calcium. The drug can also cross the blood–brain barrier, which increases its clinical use to target SK channels in the brain. | |||
| • 1-EBIO (EC50 of 630 μM for SK1, 500 μM to 1 mM for SK2, and 170 μM to 1 mM for SK3) increases calcium sensitivity, which increases SK channel activity. • 1-EBIO activates SK channels by binding both to the CaMBD and to CaM on the channel’s C terminus. • NS309 (EC50 10–20 nM for KCa3.1 and approximately 600 nM for KCa2 channels) shares the same binding site as 1-EBIO, riluzole and CyPPA. • SKS-11 and SKS-14 are highly potent SK activators. These chemicals share the same binding site as 1-EBIO and NS309 and bind through strong electrostatic bonds with the channel and lock them in an open state. • CyPPA has a high specificity toward SK2 and SK3 channels but not SK1 channels. Isoform-specific SK channel modulators facilitate targeting specific regions depending on the isoform expression. | |||
| • Cesium and ZD7288 (IC50 approximately 10 μM) are specific blockers of HCN channels. The IC50 values for blocking the four channel isoforms are similar owing to a high structural homogeneity between the different isoforms. • These blockers produce a hyperpolarizing shift in the activation voltage of HCN channels and reduce maximal channel conductance. • Alanine 425 and isoleucine 432 on S6 are crucial for binding of ZD7288 to HCN channels. • Ivabradine (IC50 approximately 1–2 μM) and clonidine (IC50 approximately 10 μM) are specific HCN4 and HCN1 blockers, which bind to the intracellular side of the channel. • Loperamide (IC50 approximately 4.9–11 μM) acts extracellularly and binds to the S1-S2 region on HCN1 channels. • Capsazepine (IC50 approximately 8 μM) is another specific HCN1 and HCN2 channel blocker that blocks HCN channels in a dose-dependent manner | |||
| • Tanshinone has a higher specificity for HCN2 than for the other isoforms. • Fisetin (EC50 approximately 2 μM) is a flavonoid activator of HCN2 channels, which shifts the channel V1/2 toward depolarized potentials. It binds to the CNBD on the channel and shares the same binding pocket as cAMP. • Lamotrigine and Gabapentin increase HCN current amplitude but do not affect channel activation or deactivation kinetics • Gabapentin is used to treat epilepsy and specifically affects the HCN4 isoform with small effect on other HCN isoforms. | |||
| • XE991 (IC50 0.8 μM) and linopirdine (IC50 5 μM) are non–isoform-specific Kv7 blockers. • Chromanol 293B, HMR1556, L-768, 673, JNJ282, and JNJ303 can block only Kv7.1 when bound to KCNE1 and KCNE3. | |||
| • Retigabine is a Kv7 channel activator that produces a hyperpolarization shift in the activation voltage, accelerates the activation kinetics of the channels, and slows the channel deactivation rate, • Retigabine can activate Kv7.2, 7.3, 7.4, and 7.5 but not Kv7.1. • Retigabine binds at the pore regions, where an interaction with a tryptophan residue at the cytoplasmic site of the S5 domain is crucial, thereby stabilizing the open state of the Kv7 channels. • Gabapentin is also a potent activator of Kv7.2/7.3 heteromeric channels as well as Kv7.3 and 7.5 homomeric channels. It does not act on homomeric Kv7.2 and 7.4 channels • Zinc pyrithione binding occurs through a leucine residue in S5 and an alanine residue in the linker region between S5 and the pore. It has a high specificity of blocking Kv7.2 homomeric channels ( |
The table summarizes various neurological anomalies dependent on the altered activity of the mAHP channels and their chemical modulators, which can alleviate the symptoms along with corresponding references.